Binding and internalization of NGR-peptide-targeted liposomal doxorubicin (TVT-DOX) in CD13-expressing cells and its antitumor effects

Anti-Cancer Drugs

Volumn 18, Issue 10, 2007, Pages 1189-1200

  Garde, Seema V ^a   Forté, André J ^a   Ge, Michael ^a   Lepekhin, Eugene A ^a   Panchal, Chandra J ^a   Rabbani, Shafaat A ^b   Wu, Jinzi J ^a  

^a Ambrilia Biopharma Inc   (Canada)

^b MCGILL UNIVERSITY HEALTH CENTRE   (Canada)

Author keywords

Aspargine glycine arginine (NGR); CD13; NGR liposomal doxorubicin; Vascular targeting

Indexed keywords

1,2 DISTEAROYLGLYCERO 3 PHISPHOETHANOLAMINE N MACROGOL 2000; ARGININE; ASPARAGINE; BAFILOMYCIN A1; DOXORUBICIN; DRUG CARRIER; GLYCINE; MACROGOL 2000; MICROSOMAL AMINOPEPTIDASE; UNCLASSIFIED DRUG;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ANTINEOPLASTIC ACTIVITY; ARTICLE; CANCER CELL CULTURE; CANCER INHIBITION; CELL NUCLEUS; COLON CANCER; CONTROLLED STUDY; CYTOTOXICITY; DRUG BINDING; DRUG EFFICACY; DRUG FORMULATION; ENDOTHELIUM CELL; FEMALE; FIBROSARCOMA; HUMAN; HUMAN CELL; IMMUNOFLUORESCENCE; IN VITRO STUDY; INTERNALIZATION; KAPOSI SARCOMA; MALE; MOUSE; NONHUMAN; PRIORITY JOURNAL; PROSTATE CANCER; PROTEIN EXPRESSION; TUMOR VASCULARIZATION; UMBILICAL VEIN;

ANIMALS; ANTIGENS, CD13; ANTINEOPLASTIC AGENTS; BIOLOGICAL TRANSPORT; CELL LINE, TUMOR; COLONIC NEOPLASMS; DOXORUBICIN; DRUG RESISTANCE, NEOPLASM; ENDOCYTOSIS; ENDOSOMES; HUMANS; LIPOSOMES; MALE; MICE; MICE, NUDE; OLIGOPEPTIDES; PROSTATIC NEOPLASMS; PROTEIN BINDING;

EID: 34748846833     PISSN: 09594973     EISSN: None     Source Type: Journal    
DOI: 10.1097/CAD.0b013e3282a213ce     Document Type: Article

References (36)

1. Matter A. Tumor angiogenesis as a therapeutic target. Drug Discov Today 2001; 6:1005-1024.
2. Thorpe PE, Chaplin DJ, Blakey DC. The first international conference on vascular targeting: meeting overview. Cancer Res 2003; 63:1144-1147.
3. Folkman J. Role of angiogenesis in tumor growth and metastasis. Semin Oncol 2002; 29:15-18.
4. Jain RK. Molecular regulation of vessel maturation. Nat Med 2003; 9:685-693.
5. Nicholson B, Schaefer G, Theodorescu D. Angiogenesis in prostate cancer: biology and therapeutic opportunities. Cancer Metastasis Rev 2001; 20:297-319.
6. Brooks PC, Montgomery AM, Rosenfeld M, Reisfeld RA, Hu T, Klier G, et al. Integrin alpha v beta 3 antagonists promote tumor regression by inducing apoptosis of angiogenic blood vessels. Cell 1994; 79:1157-1164.
7. Pasqualini R, Koivunen E, Kain R, Lahdenranta J, Sakamoto M, Stryhn A, et al. Aminopeptidase N is a receptor for tumor-homing peptides and a target for inhibiting angiogenesis. Cancer Res 2000; 60:722-727.
8. Feng D, Nagy JA, Brekken RA, Pettersson A, Manseau EJ, Pyne K, et al. Ultrastructural localization of the vascular permeability factor/vascular endothelial growth factor (VPF/VEGF) receptor-2 (FLK-1, KDR) in normal mouse kidney and in the hyperpermeable vessels induced by VPF/VEGF-expressing tumors and adenoviral vectors. J Histochem Cytochem 2000; 48:545-556.
9. Ruoslahti E. Specialization of tumour vasculature. Nat Rev Cancer 2002; 2:83-90.
10. Chang SS, O'Keefe DS, Bacich DJ, Reuter VE, Heston WD, Gaudin PB. Prostate-specific membrane antigen is produced in tumor-associated neovasculature. Clin Cancer Res 1999; 5:2674-2681.
11. Alessi P, Ebbinghaus C, Neri D. Molecular targeting of angiogenesis. Biochim Biophys Acta 2004; 1654:39-49.
12. Arap W, Pasqualini R, Ruoslahti E. Cancer treatment by targeted drug delivery to tumor vasculature in a mouse model. Science 1998; 279:377-380.
13. Zhang Z, Hatta H, Ito T, Nishimoto S. Synthesis and photochemical properties of photoactivated antitumor prodrugs releasing 5-fluorouracil. Org Biomol Chem 2005; 3:592-596.
14. Zhang Z, Hatta H, Tanabe K, Nishimoto S. A new class of 5-fluoro-2′-deoxyuridine prodrugs conjugated with a tumor-homing cyclic peptide CNGRC by ester linkers: synthesis, reactivity, and tumor-cell-selective cytotoxicity. Pharm Res 2005; 22:381-389.
15. O'Connell PJ, Gerkis V, d'Apice AJ. Variable O-glycosylation of CD13 (aminopeptidase N). J Biol Chem 1991; 266:4593-4597.
16. Colombo G, Curnis F, de Mori GM, Gasparri A, Longoni C, Sacchi A, et al. Structure-activity relationships of linear and cyclic peptides containing the NGR tumor-homing motif. J Biol Chem 2002; 277:47891-47897.
17. Curnis F, Arrigoni G, Sacchi A, Fischetti L, Arap W, Pasqualini R, et al. Differential binding of drugs containing the NGR motif to CD13 isoforms in tumor vessels, epithelia, and myeloid cells. Cancer Res 2002; 62:867-874.
18. Ellerby HM, Arap W, Ellerby LM, Kain R, Andrusiak R, Rio GD, et al. Anti-cancer activity of targeted pro-apoptotic peptides. Nat Med 1999; 5:1032-1038.
19. Grifman M, Trepel M, Speece P, Gilbert LB, Arap W, Pasqualini R, et al. Incorporation of tumor-targeting peptides into recombinant adeno-associated virus capsids. Mol Ther 2001; 3:964-975.
20. Curnis F, Sacchi A, Borgna L, Magni F, Gasparri A, Corti A. Enhancement of tumor necrosis factor alpha antitumor immunotherapeutic properties by targeted delivery to aminopeptidase N (CD13). Nat Biotechnol 2000; 18:1185-1190.
21. Pastorino F, Brignole C, Marimpietri D, Cilli M, Gambini C, Ribatti D, et al. Vascular damage and anti-angiogenic effects of tumor vessel-targeted liposomal chemotherapy. Cancer Res 2003; 63:7400-7409.
22. Park JW, Hong K, Carter P, Asgari H, Guo LY, Keller GA, et al. Development of anti-p185HER2 immunoliposomes for cancer therapy. Proc Natl Acad Sci U S A 1995; 92:1327-1331.
23. Saul JM, Annapragada A, Natarajan JV, Bellamkonda RV. Controlled targeting of liposomal doxorubicin via the folate receptor in vitro. J Control Release 2003; 92:49-67.
24. Van Hensbergen Y, Broxterman HJ, Elderkamp YW, Lankelma J, Beers JC, Heijn M, et al. A doxorubicin-CNGRC-peptide conjugate with prodrug properties. Biochem Pharmacol 2002; 63:897-908.
25. Allen TM, Hansen CB, de Menezes DEL. Pharmacokinetics of long-circulating liposomes. Adv Drug Deliv Rev 1995; 16:267-284.
26. Coukell AJ, Spencer CM. Polyethylene glycol-liposomal doxorubicin. A review of its pharmacodynamic and pharmacokinetic properties, and therapeutic efficacy in the management of AIDS-related Kaposi's sarcoma. Drugs 1997; 53:520-538.
27. Gabizon A, Martin F. Polyethylene glycol-coated (pegylated) liposomal doxorubicin. Rationale for use in solid tumours. Drugs 1997; 54 (Suppl 4): 15-21.
28. Gordon AN, Granai CO, Rose PG, Hainsworth J, Lopez A, Weissman C, et al. Phase II study of liposomal doxorubicin in platinum- and paclitaxel-refractory epithelial ovarian cancer. J Clin Oncol 2000; 18:3093-3100.
29. Northfelt DW, Dezube BJ, Thommes JA, Levine R, von Roenn JH, Dosik GM, et al. Efficacy of pegylated-liposomal doxorubicin in the treatment of AIDS-related Kaposi's sarcoma after failure of standard chemotherapy. J Clin Oncol 1997; 15:653-659.
30. Charrois GJ, Allen TM. Multiple injections of pegylated liposomal doxorubicin: pharmacokinetics and therapeutic activity. J Pharmacol Exp Ther 2003; 306:1058-1067.
31. Taatjes DJ, Koch TH. Nuclear targeting and retention of anthracycline antitumor drugs in sensitive and resistant tumor cells. Curr Med Chem 2001; 8:15-29.
32. Tseng YL, Liu JJ, Hong RL. Translocation of liposomes into cancer cells by cell-penetrating peptides penetratin and tat: a kinetic and efficacy study. Mol Pharmacol 2002; 62:864-872.
33. Bayer N, Schober D, Prchla E, Murphy RF, Blaas D, Fuchs R. Effect of bafilomycin A1 and nocodazole on endocytic transport in HeLa cells: implications for viral uncoating and infection. J Virol 1998; 72:9645-9655.
34. Yokoyama Y, Ramakrishnan S. Addition of an aminopeptidase N-binding sequence to human endostatin improves inhibition of ovarian carcinoma growth. Cancer 2005; 104:321-331.
35. Johnson JI, Decker S, Zaharevitz D, Rubinstein LV, Venditti JM, Schepartz S, et al. Relationships between drug activity in NCI preclinical in vitro and in vivo models and early clinical trials. Br J Cancer 2001; 84:1424-1431.
36. Wallace KB. Doxorubicin-induced cardiac mitochondrionopathy. Pharmacol Toxicol 2003; 93:105-115.